UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 233

Sortiert nach

Negative feedback and adaptive resistance to the targeted therapy of cancer

Cancer discovery, 2012-04, Vol.2 (4), p.311-319

Chandarlapaty, Sarat

2012

Link zum Volltext

Verfügbarkeit prüfen

Unlocking the potential of antibody-drug conjugates for cancer therapy

Nature reviews. Clinical oncology, 2021-06, Vol.18 (6), p.327-344

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular Pathways: HER3 Targeted Therapy

Clinical cancer research, 2014-03, Vol.20 (6), p.1410-1416

2014

Link zum Volltext

Verfügbarkeit prüfen

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

Expert review of anticancer therapy, 2011-02, Vol.11 (2), p.263-275

2011

Link zum Volltext

Verfügbarkeit prüfen

Reversible histone glycation is associated with disease-related changes in chromatin architecture

Nature communications, 2019-03, Vol.10 (1), p.1289-1289, Article 1289

2019

Link zum Volltext

Verfügbarkeit prüfen

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Nature communications, 2021-11, Vol.12 (1), p.6667-6667, Article 6667

2021

Link zum Volltext

Verfügbarkeit prüfen

Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders

Journal of medicinal chemistry, 2019-08, Vol.62 (16), p.7575-7582

2019

Link zum Volltext

Verfügbarkeit prüfen

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

Cancer cell, 2018-12, Vol.34 (6), p.893-905.e8

2018

Link zum Volltext

Verfügbarkeit prüfen

PTEN is a protein tyrosine phosphatase for IRS1

Nature structural & molecular biology, 2014-06, Vol.21 (6), p.522

2014

Link zum Volltext

Verfügbarkeit prüfen

Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis

Molecular cell, 2021-02, Vol.81 (4), p.708-723.e5

2021

Link zum Volltext

Verfügbarkeit prüfen

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists

Cancer discovery, 2017-03, Vol.7 (3), p.277-287

2017

Link zum Volltext

Verfügbarkeit prüfen

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR + , HER2 - advanced breast cancer: results from BOLERO-2

British journal of cancer, 2017-03, Vol.116 (6), p.726-730

2017

Link zum Volltext

Verfügbarkeit prüfen

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

Cancer cell, 2011-05, Vol.19 (5), p.575-586

2011

Link zum Volltext

Verfügbarkeit prüfen

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update

Journal of clinical oncology, 2022-08, Vol.40 (23), p.JCO2200520-2655

2022

Link zum Volltext

Verfügbarkeit prüfen

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

Cancer discovery, 2011-08, Vol.1 (3), p.248-259

2011

Link zum Volltext

Verfügbarkeit prüfen

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Science translational medicine, 2015-04, Vol.7 (283), p.283ra51

2015

Link zum Volltext

Verfügbarkeit prüfen

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

Clinical cancer research, 2012-12, Vol.18 (24), p.6784-6791

2012

Link zum Volltext

Verfügbarkeit prüfen

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

Cancer discovery, 2022-02, Vol.12 (2), p.356-371

2022

Link zum Volltext

Verfügbarkeit prüfen

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Nature communications, 2022-07, Vol.13 (1), p.4116-4116, Article 4116

2022

Link zum Volltext

Verfügbarkeit prüfen

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2⁺ breast cancer patients

Proceedings of the National Academy of Sciences - PNAS, 2011-03, Vol.108 (9), p.3761-3766

2011

Link zum Volltext

Verfügbarkeit prüfen

Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations

Modern pathology, 2022-03, Vol.35 (3), p.396-402

2022

Link zum Volltext

Verfügbarkeit prüfen

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

PloS one, 2008-08, Vol.3 (8), p.e3065

2008

Link zum Volltext

Verfügbarkeit prüfen

Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer

Cell reports (Cambridge), 2023-11, Vol.42 (11), p.113198-113198, Article 113198

2023

Link zum Volltext

Verfügbarkeit prüfen

Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association

Breast cancer research : BCR, 2019-07, Vol.21 (1), p.82-82, Article 82

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 233

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(220)
Mit Volltextzugriff
(212)

Publikationsform

Sprache

Englisch
(233)
Japanisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Negative feedback and adaptive resistance to the targeted therapy of cancer

Unlocking the potential of antibody-drug conjugates for cancer therapy

Molecular Pathways: HER3 Targeted Therapy

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

Reversible histone glycation is associated with disease-related changes in chromatin architecture

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation

PTEN is a protein tyrosine phosphatase for IRS1

Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR + , HER2 - advanced breast cancer: results from BOLERO-2

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2⁺ breast cancer patients

Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer

Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association

Suchergebnisse filtern